Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Phase II/III Chemotherapy with CAMP (CTX/ADR/MTX/PCB) vs VP-16/DAVA/CACP vs VP-16/CACP vs DAVA/CACP for Stage III Metastatic non-Small Cell Bronchogenic Carcinoma

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase III, Phase II

Treatment

Closed

under 70

UCCRC-3248
NCI-D81-014-080

Objectives

I.  Compare standard chemotherapy CAMP 
(cyclophosphamide/adriamycin/methotrexate/procarbazine) to three experimental 
combinations (DAVA/CACP, VP-16/CACP, and DAVA/VP-16/CACP) on non-small cell 
bronchogenic carcinoma.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients younger than 70 years of age 
with Stage III-M1 (metastatic) non-small cell bronchogenic carcinoma 
(epidermoid, adeno-, and large cell) with adequate cardiac (no hypertension, 
CHF, or MI within 6 months) and renal (creatinine clearance greater than 70 
ml/minute) function.  Patients must have a clearly measurable indicator lesion 
or otherwise evaluable disease (bone metastasis).  All patients must have 
histopathological documentation of lung cancer.  Electronmicroscopy will be 
performed in cases of large cell carcinoma to determine a more accurate 
histologic subtype.

Expected Enrollment

Protocol completed April 1985.

Outline

Randomized study.
Arm I:  2-Drug Combination Chemotherapy.  Vindesine, DAVA, NSC-245467; 
cis-Platinum, CACP, NSC-119875.
Arm II:  2-Drug Combination Chemotherapy.  VP-16213, VP-16, NSC-141540; CACP.
Arm III:  3-Drug Combination Chemotherapy.  VP-16; DAVA; CACP.
Arm IV:  4-Drug Combination Chemotherapy.  CAMP:  Cyclophosphamide, CTX, 
NSC-26271; Adriamycin, ADR, NSC-123127; Methotrexate, MTX, NSC-740; 
Procarbazine, PCB; NSC-77213.

Trial Contact Information

Trial Lead Organizations

University of Chicago Cancer Research Center

Harvey Golomb, MD, Protocol chair
Ph: 773-702-9200; 888-824-0200

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.